IP Library Granted Patent US 10,266,488
Granted Patent B2
US 10,266,488 · App. 15/028,386 · Granted Apr 23, 2019

4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase

Inventors: David J. Maloney (Point Of Rocks, MD); Diane K. Luci (Germantown, MD); Ajit Jadhav (Chantilly, VA); Theodore Holman (Santa Cruz, CA); Jerry L. Nadler (Norfolk, VA); Michael Holinstat (Wallingford, PA); David Taylor-Fishwick (Norfolk, VA); Anton Simeonov (Bethesda, MD); Adam Yasgar (Washington, DC); Steven McKenzie (Springfield, PA)
Assignees: Eastern Virginia Medical School; The Regents of the University of California Santa Cruz; The United States of America Department of Health and Human Services; Thomas Jefferson University
C07C311/44A61P7/02C07D211/28C07D213/76C07D217/02C07D217/22C07D235/30C07D239/69C07D261/16C07D263/58C07D277/52C07D277/82C07D295/135C07D333/36C07D417/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,266,488
App. No.
15/028,386
Granted
Apr 23, 2019
Kind
B2
Abstract

Human lipoxygenases (LOXs) are a family of iron-containing enzymes involved in catalyzing the oxidation of polyunsaturated fatty acids to provide the corresponding bioactive hydroxyeicosatetraenoic acid (HETE) metabolites. These eicosanoid signaling molecules are involved in a number of physiologic responses such as platelet aggregation, inflammation, and cell proliferation. Platelet-type 12-(S)-LOX (12-LOX) is of particular interest because of its demonstrated role in skin diseases, diabetes, platelet hemostasis, thrombosis, and cancer. Disclosed herein is the identification and medicinal chemistry optimization of a 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide-based scaffold. The compounds display nM potency against 12-LOX and excellent selectivity over related lipoxygenases and cyclooxygenases. In addition to possessing favorable ADME properties, the compounds also inhibit PAR-4 induced aggregation and calcium mobilization in human platelets, and reduce 12-HETE in mouse/human beta cells. The compounds can also be used in methods for treating or preventing a 12-lipoxygenase mediated disease or disorder.

Claims (17)

1. A compound that is

or a pharmaceutically acceptable salt thereof.

2. A compound that is

or a pharmaceutically acceptable salt thereof.

3. A compound that is

or a pharmaceutically acceptable salt thereof.

4. A compound of Formula (I)

wherein R 1 is methoxy;

R 2 is H; and

R 3 is selected from the group consisting of 2-benzothiazole, 4-methyl-2-benzothiazole, 6-fluoro-2-benzothiazole, 6-methoxy-2-benzothiazole, 2-benzoxazole, 2-benzimidazole, 2-thiophene, 4-methyl-2-thiazole, 5-methyl-2-thiazole, 4,5-methyl-2-thiazole, 4-phenyl-2-thiazole, 3-quinoline, 8-isoquinoline, phenyl, 1,4-biphenyl, 1-naphthalene, 2-naphthalene, 3-piperazine-phenyl, 4-piperidine-phenyl, 3-piperidine-phenyl, 2-pyridine, 3-pyridine, 4-piperazine-3-pyridine, 3-tert-butyl-phenyl, 3-morpholine-phenyl, 4N-boc-piperidine-3-phenyl, and 3-isopropyl-phenyl.

5. The compound of claim 4 , wherein R 3 is selected from the group consisting of 2-benzothiazole, 4-methyl-2-benzothiazole, 6-methoxy-2-benzothiazole, 2-benzoxazole, 2-benzimidazole, 2-thiophene, 4-phenyl-2-thiazole, 3-quinoline, 8-isoquinoline, phenyl, 1-napthalene, 2-napthalene, 3-tert-butyl-phenyl, 4N-boc-piperidine-3-phenyl, and 3-isopropyl-phenyl.

6. A compound of Formula (I)

wherein R 1 is Cl or H, and R 2 is Br or H, wherein when R 1 is Cl, R 2 is H, and when R 1 is H, R 2 is Br; and

R 3 is selected from the group consisting of phenyl, 4-biphenyl, thiazole, 1-napthalene, 2-napthalene, 2-benzothiazole, 3-quinoline, 8-isoquinoline, and 4-phenyl-piperidine, wherein when R 3 is 4-phenyl-piperidine, R 1 is Cl and R 2 is H.

7. The compound of claim 6 , wherein R 3 is selected from the group consisting of 1-napthalene, 2-benzothiazole, 2-napthalene.

8. A method for treating or preventing thrombosis, comprising administering to a mammal thereof a therapeutically or prophylactically effective amount of a compound of claim 4 , or salt thereof.

9. A method for treating or preventing thrombosis comprising administering to a mammal thereof a therapeutically or prophylactically effective amount of a compound of claim 6 , or salt thereof.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2016
From: MCKENZIE, STEVEN
To: THOMAS JEFFERSON UNIVERSITY
Reel/Frame 040302/0140 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2016
From: HOLINSTAT, PH.D., MICHAEL
To: THOMAS JEFFERSON UNIVERSITY
Reel/Frame 040205/0144 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2016
From: HOLMAN, PH.D., THEODORE
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SANTA CRUZ
Reel/Frame 039920/0179 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2016
From: NADLER, MD, JERRY L.; TAYLOR-FISHWICK, PH.D., DAVID
To: EASTERN VIRGINIA MEDICAL SCHOOL
Reel/Frame 039920/0330 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2016
From: MALONEY, DAVID J.; LUCI, DIANE K.; JADHAV, AJIT; SIMEONOV, ANTON; YASGAR, ADAM
To: THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH
Reel/Frame 039920/0421 →
Continuity (3)
Provisional Application 61987129 · May 1, 2014
Provisional Application 61889396 · Oct 10, 2013
Related Publication 20170001955A1 · Jan 5, 2017